Eli Lilly CEO: Developing potential coronavirus treatment at 'lightning speed’
Eli Lilly CEO: Developing antibody coronavirus therapy
Eli Lilly CEO David Ricks on partnering with AbCellera to co-develop a coronavirus therapy to help people who are sick or at risk and drug supply chains.
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.
Continue Reading Below
Eli Lilly CEO David Ricks said the pharmaceutical industry is working at "lightning speed" to develop a coronavirus treatment, and that Lilly is doing its part by collaborating with biotechnology firm AbCellera to create an antibody therapy to treat COVID-19.
"Across the industry … everybody is working around the clock, and I think at lightning speed and in ways we never have before," Ricks told FOX Business’ Maria Bartiromo on Friday.
CORONAVIRUS 'SOCIAL DISTANCING' GETTING NEW GUIDELINES FROM TRUMP ADMINISTRATION
|LLY||ELI LILLY & COMPANY||130.74||-3.61||-2.69%|
Ricks said the potential treatment would work by acquiring a blood sample from some of the early survivors of COVID-19, the disease caused by the novel coronavirus, and isolating antibodies, which is the way the body attacks viruses and infusing them into people who are sick.
“It’s an exciting approach and one of many approaches across the industry to help with this horrible situation,” he said.